Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2020-07-01; 101: 109927
DOI: 10.1016/j.pnpbp.2020.109927
Read on PubMed
1. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109927. doi:
10.1016/j.pnpbp.2020.109927. Epub 2020 Mar 12.
Confirmations, advances and recommendations for the daily care of schizophrenia
based on the French national FACE-SZ cohort.
Fond G(1), Godin O(2), Schürhoff F(3), Berna F(4), André M(5), Aouizerate B(6),
Capdevielle D(5), Chereau I(7), D’ Amato T(8), Dubertret C(9), Dubreucq J(10),
Faget C(11), Lançon C(11), Leignier S(10), Mallet J(9), Misdrahi D(12),
Passerieux C(13), Pignon B(3), Rey R(8), Szoke A(3), Urbach M(13), Vidailhet
P(14), Leboyer M(3), Boyer L(11), Llorca PM(7); FACE-SZ group.
Author information:
(1)Fondation FondaMental, Créteil, France; Aix-Marseille Univ, Faculté de
Médecine – Secteur Timone, EA 3279: CEReSS -Centre d’Etude et de Recherche sur
les Services de Santé et la Qualité de vie, 27 Boulevard Jean Moulin, Marseille
13005, France. Electronic address: .
(2)Fondation FondaMental, Créteil, France.
(3)Fondation FondaMental, Créteil, France; INSERM U955, équipe de psychiatrie
translationnelle, Créteil, France, Université Paris-Est Créteil, DHU Pe-PSY,
Pôle de Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil, France.
(4)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(5)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm, Montpellier 1061, France.
(6)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; INRA, NutriNeuro, University
of Bordeaux, U1286, Bordeaux F-33076, France.
(7)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, Clermont-Ferrand Cedex 1 BP 69 63003, France.
(8)Fondation FondaMental, Créteil, France; INSERM U1028, CNRS UMR5292, Centre de
Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe
PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, Bron
Cedex 69678, France.
(9)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, Louis
Mourier Hospital, Inserm U894, Colombes, France.
(10)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(11)Fondation FondaMental, Créteil, France; Aix-Marseille Univ, Faculté de
Médecine – Secteur Timone, EA 3279: CEReSS -Centre d’Etude et de Recherche sur
les Services de Santé et la Qualité de vie, 27 Boulevard Jean Moulin, Marseille
13005, France.
(12)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; CNRS, UMR 5287-INCIA, France.
(13)Fondation FondaMental, Créteil, France; Centre Hospitalier de Versailles,
Service de psychiatrie et d’addictologie adulte, Le Chesnay, HANDIReSP, UFR des
Sciences de la Santé Simone Veil, Université Versailles
Saint-Quentin-en-Yvelines, Versailles EA 4047, France.
(14)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.
BACKGROUND: The National FondaMental Centers of Expertise (FACE) for
Schizophrenia (SZ) have been created to shorten the gap between research and
clinical practice.
OBJECTIVES: To synthetize in a review the 10-year findings issued from the
FACE-SZ cohort analyses.
METHODS: More than 1000 patients were evaluated in 10 expert centers since 2010
with a 2-day long comprehensive standardized battery including
neuropsychological testes and physical health assessment and followed-up for
3 years.
RESULTS: 1. The phase 0 cross-sectional analyses have confirmed well-known data:
over-prescription of first-generation antipsychotics, antipsychotic polytherapy
and long-term benzodiazepine and under-prescription of clozapine, 13% of
drug-induced parkinsonism, 18% of akathisia, a mean duration of untreated
psychosis of 18 months, one third of poorly-adherent patients, 24% of metabolic
syndrome and 52% of current tobacco smokers with poor care for physical
illnesses; a yearly mean financial cost of 15,000 euro/patient. 2. FACE-SZ also
yielded additional data in insufficiently explored area: a half of major
depression issues (among them one third of undiagnosed major depression and 44%
of treated patients with unremitted depression), major depression having a
strong impact on Quality of Life independently of negative symptoms, 22% of
moderated to severe untreated physical pain. 3. FACE-SZ has explored emerging
fields of research, including development of 4 stages- model of schizophrenia,
chronic low-grade peripheral inflammation, latent Toxoplasma infection,
hypovitaminosis D, and a model for relapse prediction at 2 years.
DISCUSSION: The associated factors and implications for public health programs
were discussed. Based on the FACE-SZ findings and literature, the FACE-SZ group
has yielded recommendations to improve daily care for schizophrenia and for
future research.
Copyright © 2020 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.pnpbp.2020.109927
PMID: 32173456 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of Competing Interest None declared.